-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objectives : Psoriasis has been documented in pediatric patients following the use of tumor necrosis factor (TNF) inhibitors (TNFi) , but the association of TNFi with psoriasis in juvenile idiopathic arthritis (JIA) has not been as strong as in children As evidenced by large prospective clinical observations such as the Arthritis and Rheumatology Research Consortium
Objectives : Psoriasis has been documented in pediatric patients following the use of tumor necrosis factor (TNF) inhibitors (TNFi) , but the association of TNFi with psoriasis in juvenile idiopathic arthritis (JIA) has not been as strong as in children As evidenced by large prospective clinical observations such as the Arthritis and Rheumatology Research Consortium
Methods: De-identified data were obtained from the CARRA registry
Results: A total of 8225 patients were included, and the median follow-up time was 3.
Conclusions: In a large prospective registry of patients with JIA , we observed a nearly three-fold increase in psoriasis risk following TNFi exposure .
Conclusions: In a large prospective registry of patients with JIA , we observed a nearly three-fold increase in psoriasis risk following TNFi exposure .
Source: Zhao Y, Sullivan E, Son MB , et al .
Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA.
Annals of the Rheumatic Diseases2022; 81: 662-665.
, et al Annals of the Rheumatic Diseases 81:
Leave a message here
